Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer

S. Mitsunaga, M. Ikeda, S. Shimizu, I. Ohno, J. Furuse, M. Inagaki, S. Higashi, H. Kato, K. Terao, A. Ochiai

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Background:With this study, we sought to characterise the impact of pro-inflammatory cytokines on the outcomes of gemcitabine monotherapy (GEM) in patients with pancreatic cancer (PC).Methods:Treatment-naive patients with advanced PC and no obvious infections were eligible for enrolment. All of the patients were scheduled to undergo systemic chemotherapy. Serum pro-inflammatory cytokines were measured using an electro-chemiluminescence assay method before chemotherapy. High cytokine levels were defined as values greater than the median. Clinical data were collected prospectively.Results:Sixty patients who received GEM were included in the analysis. High IL-6 and IL-1β levels were poor prognostic factors for overall survival in a multivariate analysis (P=0.011 and P=0.048, respectively). Patients with both a high IL-6 level and a high IL-1β level exhibited shortened overall and progression-free survival, a reduction in the tumour control rate, and a high dose intensity of GEM compared with patients with low levels of both IL-6 and IL-1β.Conclusion: The serum levels of IL-6 and IL-1β predict the efficacy of GEM in patients with advanced PC.

Original languageEnglish
Pages (from-to)2063-2069
Number of pages7
JournalBritish Journal of Cancer
Volume108
Issue number10
DOIs
Publication statusPublished - May 2013
Externally publishedYes

Fingerprint

gemcitabine
Pancreatic Neoplasms
Interleukin-1
Interleukin-6
Serum
Cytokines
Drug Therapy
Luminescence
Disease-Free Survival
Multivariate Analysis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mitsunaga, S., Ikeda, M., Shimizu, S., Ohno, I., Furuse, J., Inagaki, M., ... Ochiai, A. (2013). Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. British Journal of Cancer, 108(10), 2063-2069. https://doi.org/10.1038/bjc.2013.174

Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. / Mitsunaga, S.; Ikeda, M.; Shimizu, S.; Ohno, I.; Furuse, J.; Inagaki, M.; Higashi, S.; Kato, H.; Terao, K.; Ochiai, A.

In: British Journal of Cancer, Vol. 108, No. 10, 05.2013, p. 2063-2069.

Research output: Contribution to journalArticle

Mitsunaga, S, Ikeda, M, Shimizu, S, Ohno, I, Furuse, J, Inagaki, M, Higashi, S, Kato, H, Terao, K & Ochiai, A 2013, 'Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer', British Journal of Cancer, vol. 108, no. 10, pp. 2063-2069. https://doi.org/10.1038/bjc.2013.174
Mitsunaga, S. ; Ikeda, M. ; Shimizu, S. ; Ohno, I. ; Furuse, J. ; Inagaki, M. ; Higashi, S. ; Kato, H. ; Terao, K. ; Ochiai, A. / Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. In: British Journal of Cancer. 2013 ; Vol. 108, No. 10. pp. 2063-2069.
@article{44ce79dfb7b64fe6a17153c0882e57b0,
title = "Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer",
abstract = "Background:With this study, we sought to characterise the impact of pro-inflammatory cytokines on the outcomes of gemcitabine monotherapy (GEM) in patients with pancreatic cancer (PC).Methods:Treatment-naive patients with advanced PC and no obvious infections were eligible for enrolment. All of the patients were scheduled to undergo systemic chemotherapy. Serum pro-inflammatory cytokines were measured using an electro-chemiluminescence assay method before chemotherapy. High cytokine levels were defined as values greater than the median. Clinical data were collected prospectively.Results:Sixty patients who received GEM were included in the analysis. High IL-6 and IL-1β levels were poor prognostic factors for overall survival in a multivariate analysis (P=0.011 and P=0.048, respectively). Patients with both a high IL-6 level and a high IL-1β level exhibited shortened overall and progression-free survival, a reduction in the tumour control rate, and a high dose intensity of GEM compared with patients with low levels of both IL-6 and IL-1β.Conclusion: The serum levels of IL-6 and IL-1β predict the efficacy of GEM in patients with advanced PC.",
author = "S. Mitsunaga and M. Ikeda and S. Shimizu and I. Ohno and J. Furuse and M. Inagaki and S. Higashi and H. Kato and K. Terao and A. Ochiai",
year = "2013",
month = "5",
doi = "10.1038/bjc.2013.174",
language = "English",
volume = "108",
pages = "2063--2069",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer

AU - Mitsunaga, S.

AU - Ikeda, M.

AU - Shimizu, S.

AU - Ohno, I.

AU - Furuse, J.

AU - Inagaki, M.

AU - Higashi, S.

AU - Kato, H.

AU - Terao, K.

AU - Ochiai, A.

PY - 2013/5

Y1 - 2013/5

N2 - Background:With this study, we sought to characterise the impact of pro-inflammatory cytokines on the outcomes of gemcitabine monotherapy (GEM) in patients with pancreatic cancer (PC).Methods:Treatment-naive patients with advanced PC and no obvious infections were eligible for enrolment. All of the patients were scheduled to undergo systemic chemotherapy. Serum pro-inflammatory cytokines were measured using an electro-chemiluminescence assay method before chemotherapy. High cytokine levels were defined as values greater than the median. Clinical data were collected prospectively.Results:Sixty patients who received GEM were included in the analysis. High IL-6 and IL-1β levels were poor prognostic factors for overall survival in a multivariate analysis (P=0.011 and P=0.048, respectively). Patients with both a high IL-6 level and a high IL-1β level exhibited shortened overall and progression-free survival, a reduction in the tumour control rate, and a high dose intensity of GEM compared with patients with low levels of both IL-6 and IL-1β.Conclusion: The serum levels of IL-6 and IL-1β predict the efficacy of GEM in patients with advanced PC.

AB - Background:With this study, we sought to characterise the impact of pro-inflammatory cytokines on the outcomes of gemcitabine monotherapy (GEM) in patients with pancreatic cancer (PC).Methods:Treatment-naive patients with advanced PC and no obvious infections were eligible for enrolment. All of the patients were scheduled to undergo systemic chemotherapy. Serum pro-inflammatory cytokines were measured using an electro-chemiluminescence assay method before chemotherapy. High cytokine levels were defined as values greater than the median. Clinical data were collected prospectively.Results:Sixty patients who received GEM were included in the analysis. High IL-6 and IL-1β levels were poor prognostic factors for overall survival in a multivariate analysis (P=0.011 and P=0.048, respectively). Patients with both a high IL-6 level and a high IL-1β level exhibited shortened overall and progression-free survival, a reduction in the tumour control rate, and a high dose intensity of GEM compared with patients with low levels of both IL-6 and IL-1β.Conclusion: The serum levels of IL-6 and IL-1β predict the efficacy of GEM in patients with advanced PC.

UR - http://www.scopus.com/inward/record.url?scp=84878562029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878562029&partnerID=8YFLogxK

U2 - 10.1038/bjc.2013.174

DO - 10.1038/bjc.2013.174

M3 - Article

C2 - 23591198

AN - SCOPUS:84878562029

VL - 108

SP - 2063

EP - 2069

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 10

ER -